Randomized phase III study of Gemcitabine/cisplatin versus mitomycin/ifosfamide/cisplatin in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Scagliotti, G
Crino, L
Conte, PF
Rinaldi, M
De Marinis, F
Gridelli, C
机构：
[1] Univ Turin, Dept Clin & Biol Sci, Turin, Italy
[2] Osped Policlin, Div Med Oncol, Perugia, Italy
[3] St Chiara Hosp, Div Med Oncol, Pisa, Italy
[4] Med Oncol, Rome, Italy
[5] Dept Pneumol, Rome, Italy
[6] Natl Canc Inst, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
407P
引用
收藏
页码：85 / 85
页数：1
相关论文
共 50 条
  • [21] Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC).
    Zhang, Y
    Zhang, L
    Li, N
    Xu, F
    Pan, ZK
    Guang, ZZ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
  • [22] Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III randomized trial
    Georgoulias, V.
    Ardavanis, A.
    Tsiafaki, X.
    Agelidou, A.
    Syrigos, K.
    Polyzos, A.
    Kakolyris, S.
    Kouroussis, Ch
    Androulakis, N.
    Chatzidaki, D.
    ANNALS OF ONCOLOGY, 2004, 15 : 169 - 169
  • [23] A phase II trial of the combination of gemcitabine, ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer
    Vadell-Nadal, C
    Nogué-Aliguer, M
    Fabregat-Mayol, X
    Saigí-Grau, E
    Gallén-Castillo, M
    LUNG CANCER, 2000, 28 (02) : 109 - 115
  • [24] Significantly higher survival with Gemcitabine-cisplatin vs cisplatin in advanced non-small cell lung cancer (NSCLC): Final results from an international randomized phase III study
    Sandler, A
    Denham, C
    von Pawel, J
    Cormier, Y
    Gatzemeier, U
    Mattson, K
    Manegold, C
    Gregor, A
    Blatter, J
    Einhorn, L
    ANNALS OF ONCOLOGY, 1998, 9 : 85 - 85
  • [25] Randomized phase II study of cisplatin/vinorelbine vs cisplatin/gemcitabine vs vinorelbine/gemcitabine in patients with advanced non-small cell lung cancer
    Tsai, CM
    Perng, RP
    Wang, GS
    Chen, YM
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 78 - 78
  • [26] Vinorelbine, ifosfamide and cisplatin in advanced non-small cell lung cancer
    Tan, EH
    Ang, PT
    Wee, J
    Fong, KW
    Leong, SS
    Khoo, KS
    ACTA ONCOLOGICA, 1999, 38 (05) : 619 - 622
  • [27] Paclitaxel/gemcitabine versus paclitaxel/vinorelbine in advanced non-small cell lung cancer (NSCLC): A phase III randomized study
    Kosmidis, P. A.
    Timotheadou, E.
    Koutras, A.
    Pentheroudakis, G.
    Christodoulou, C.
    Dimopoulos, A. M.
    Bafaloukos, D.
    Samantas, E.
    Pectasides, D.
    Syrigos, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: A phase III randomized study of the London Lung Cancer Group
    Rudd, RM
    Gower, NH
    Spiro, SG
    Eisen, TG
    Harper, PG
    Littler, JAH
    Hatton, M
    Johnson, PWM
    Martin, WMC
    Rankin, EM
    James, LE
    Gregory, WM
    Qian, W
    Lee, SM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) : 142 - 153
  • [29] Phase II study of regimen of gemcitabine and cisplatin in advanced non-small cell lung cancer
    Chen, SCH
    Lin, MC
    Chang, JWC
    Wang, SW
    Lee, CH
    Tsao, TCY
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2000, 30 (11) : 494 - 498
  • [30] A phase II study of a modified cisplatin and Gemcitabine regimen in advanced non-small cell lung cancer (NSCLC): An ongoing study
    Gonzalez-Martin, A
    Garcia-Lopez, JL
    Crespo, C
    Lastra, E
    Pedraza, M
    Cerrato, L
    Rios, A
    Moyano, AJ
    Garrido, P
    ANNALS OF ONCOLOGY, 1998, 9 : 98 - 98
12345